Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
Crossref DOI link: https://doi.org/10.1007/s12325-019-01046-w
Published Online: 2019-08-07
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ishizawa, Kenichi
Yanai, Tomoko
Funding for this research was provided by:
Takeda Pharmaceutical Company
Text and Data Mining valid from 2019-08-07
Version of Record valid from 2019-08-07
Article History
Received: 5 March 2019
First Online: 7 August 2019